Oncology Corporate Profile
Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|G17DT||polyclonal antibody stimulator||Gastric cancer||III|
|G17DT||polyclonal antibody stimulator||Pancreatic cancer||III|
|G17DT||polyclonal antibody stimulator||Colorectal cancer||II|
View additional information on product candidates here »